BC Week In Review | Jan 18, 2010
Company News

Boulder Diagnostics Inc., Multimmune deal

Boulder Diagnostics will develop a blood-based heat shock protein 70 (Hsp70) lateral flow point-of-care test for Multimmune to determine which patients would benefit from hsp-70-derived treatments. The test will also evaluate the correlation of elevated...
BC Innovations | Oct 15, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Heat shock protein 70 (Hsp70) In vitro and mouse studies suggest that 2-phenylethynesulfonamide (PES) inhibits Hsp70 and could help treat cancer. In cultured tumor...
Items per page:
1 - 2 of 2